Target
CLDN6
3 abstracts
Abstract
Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors.Org: University of California Los Angeles Medical Center, Mayo Clinic, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Vanadro LLC, University of Southern California Marshall School of Business,
Abstract
A phase I/II dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with prospectively confirmed claudin 6-positive solid tumors.Org: Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Virginia Cancer Specialists, BioNTech,
Abstract
CLDN6 CAR-T cell therapy of relapsed/refractory solid tumors ± a CLDN6-encoding mRNA vaccine: Dose escalation data from the BNT211-01 phase 1 trial using an automated product.Org: Friedrich-Alexander University Erlangen-Nuremberg, Netherlands Cancer Institute, Hannover Medical School, University Hospital Hamburg Eppendorf, University Medical Center Mainz,